Shots:

• Medigene to receive $29.37M up front & research funding & will be eligible to receive development, regulatory & commercial milestone along with tiered deferred option fees & royalties. BioNTech gets an exclusive option to acquire additional TCRs in Medigene’s discovery pipeline & get the license to Medigene’s PD1-41BB switch receptor & precision pairing technologies
• BioNTech will hold exclusive commercialization rights globally on all TCR therapies & will lead the global development of the product
• The collaboration will use BioNTech’s immunotherapy capabilities & Medigene’s TCR discovery platform to develop TCR immunotherapies for multiple solid tumor targets selected by BioNTech

 Ref: Globe Newswire | Image: Bloomberg